Updated

Shares of Chinese biopharmaceutical companies rose Monday after a report indicated the U.S. government may continue permitting most drug licensing deals between American and Chinese firms, easing fears of a broader crackdown on cross-border pharma partnerships. The move offers relief to investors who had worried that geopolitical tensions between Washington and Beijing could spill over into restrictions on biotech collaboration, an area that has become increasingly important for drug development pipelines on both sides.